Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

J.-Y. Douillard(REseau NAtional de Rpe interDisciplinaire), Salvatore Siena(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), J Cassidy(Beatson West of Scotland Cancer Centre), Josep Tabernero(Vall d'Hebron Hospital Universitari), Ronald L. Burkes(Mount Sinai Hospital), Mario Barugel, Yves Humblet(UCLouvain), G. Bodoky(Unified Szent István and Szent László Hospital), David Cunningham(Royal Marsden NHS Foundation Trust), Jacek Jassem(Gdańsk Medical University), Fernando Rivera(Marqués de Valdecilla University Hospital), Ilona Kocáková(Masaryk University), Paul Ruff(University of the Witwatersrand), Maria Błasińska-Morawiec(Copernicus Memorial Hospital), Martin Šmakal(Nemocnice Na Pleši), J.-L. Canon(Grand Charleroi Hospital), M. Rother(Credit Valley Hospital), Kelly S. Oliner(Amgen (United States)), Ying Tian(Amgen (United States)), Feng Xu(Amgen (United States)), R. Sidhu(Amgen (United States))
Annals of Oncology
April 9, 2014
10.1093/annonc/mdu141
Cited by 603Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis